The Latest
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Venture funding involving the firms tracked by BioPharma Dive is currently behind last year’s pace, with about $2.7 billion doled out through March 13 compared to around $3.8 billion by this time in 2025.
Updated 3 hours ago -
Permission granted by MilliporeSigma
Sponsored by MilliporeSigmaNavigating the PPQ process: Proven strategies to safeguard quality for cell and gene therapies
An often overlooked but critically important step along the path from bench to bedside, PPQ often results in delays and potential non-compliance issues without proper planning.
-
Getty Images
Emerging biotechWith $100M, Vima pursues an oral drug for movement disorders
Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or Parkinson's disease regain control of movement.
-
Tasos Katopodis via Getty Images
Trump administrationFDA to unify agency’s ‘fragmented’ safety surveillance system
Combining the disparate databases used to detect potential issues with drugs, vaccines and other products into a single dashboard will enhance their utility and cut costs, the agency said.
-
Scott Olson via Getty Images
China competitionLilly unveils $3 billion production expansion in China
The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.
-
Jacob Bell/BioPharma Dive
Biogen builds case for Spinraza successor with fresh data
More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.
-
Courtesy of AbbVie
Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial
UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.
-
Sean Gallup via Getty Images
BioNTech founders to step down and helm new mRNA startup
Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company dedicated to mRNA discovery work.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Salspera could be the seventh biotech in 2026 to go public, revealing this week that it’s set terms for an IPO that could net up to $91 million and support late-stage testing of a pancreatic cancer drug.
Updated March 12, 2026 -
Courtesy of UniQure
UniQure leads genetic medicine biotech rally after news of Prasad’s exit
Vinay Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many developers rose on the chance of a more industry-friendly successor.
-
Permission granted by Vertex Pharmaceuticals
Vertex kidney disease drug hits mark in late-stage study
Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.
Updated March 10, 2026 -
Getty Images
Bristol Myers claims success in study of another next-gen blood cancer drug
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.
-
Courtesy of CSL
CSL breaks ground on $1.5B Illinois immunoglobulin plant expansion
The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.
-
Retrieved from FDA.
Trump administrationVinay Prasad, controversial FDA leader, to again depart agency
Prasad’s planned departure, expected at the end of April, culminates a tumultuous term in which he reworked vaccine guidelines and was criticized for his office’s stance on several rare disease drugs.
Updated March 7, 2026 -
Getty Images
News roundupXenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy
Xenon shares skyrocketed nearly 50% on results that handily beat Wall Street expectations. Elsewhere, Capricor got a decision date for a spurned cell therapy and AbbVie and Regeneron showcased obesity data.
-
Getty Images
Roche’s prized breast cancer pill fails closely watched study
The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Servier’s buyout of Day One is the year’s second-largest biotech acquisition so far, trailing only Gilead’s $7.8 billion purchase of cell therapy maker Arcellx.
Updated March 6, 2026 -
Courtesy of Hims & Hers
Obesity drugsNovo, Hims reach deal to sell GLP-1 drugs together
The agreement ends a messy dispute that began when the telehealth firm attempted to sell a compounded form of Novo’s Wegovy pill at a cheaper price.
-
Courtesy of Ipsen
Ipsen to withdraw cancer drug acquired in buyout due to safety concerns
Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme and that it has struggled to sell.
-
Getty Images
Servier to build cancer drug pipeline with $2.5B purchase of Day One
The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved therapy for certain hard-to-treat brain tumors that affect children.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Sanofi reached a deal for rights to a drug already on the market in China, while UCB is the latest to bet on the ability of T cell engagers to treat autoimmune conditions.
Updated March 4, 2026 -
Getty Images
FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
The regimen’s clearance in early multiple myeloma was the third approval under the agency’s controversial “national priority” voucher program and issued only 55 days after the review began.
-
Permission granted by Roche
Obesity drugsRoche, Zealand shares fall on ‘undifferentiated’ obesity drug results
An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than investors had hoped, leading some analysts to question its ability to stand out.
-
Scott Olson via Getty Images
Obesity drugsLilly targets employers in new bid to broaden access to obesity drugs
A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.
-
Courtesy of Teva Pharmaceutical
Blackstone puts $400M into Teva, Sanofi gut disease drug
The deal adds to a growing biotech presence for Blackstone and supports testing of a drug competing with rival therapies from Merck and Roche.
-
Getty Images
News roundup
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.
